



Bal Pharma Limited

To,
The Manager-Listing
BSE Limited
Mumbai.

13.02.2019

The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub : Outcome of the Board Meeting.
Ref : Regulation 30 of SEBI(LODR) Regulations,2015.

With reference to the above, the Board of Directors of the Company has met today and *inter alia* transacted the following business,

Approved the Un-audited financial results of the Company for the quarter and nine months ended 31.12.2018. A copy of the standalone financial results along with the limited review report issued by the statutory auditors of the Company is enclosed with this intimation.

The meeting commenced at 4 p.m and concluded at 5.00 p.m.

Please take this intimation on record.

For Bal Pharma Limited


Shailesh Siroya
Managing Director.



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India
Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58
Email : Info@balpharma.com Website : www.balpharma.com
CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813 / 19 Fax: 41570820



BAL PHARMA LIMITED

CIN: L85110KA1987PLC008368

Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099

STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2018

(Rs in Lakhs except EPS)

Sl No.	Particulars	Standalone					
		Quarter Ended			Nine Months ended		Year ended
		31 December 2018 Unaudited	30 September 2018 Unaudited	31 December 2017 Unaudited	31 December 2018 Unaudited	31 December 2017 Unaudited	31 March 2018 audited
	Income						
1	Revenue from operations	5,574.55	5,838.43	5,194.13	16,686.84	15,191.76	20,984.74
2	Other income	110.08	3.00	10.81	189.36	189.37	163.92
3	Total Income - (i)	5,684.63	5,841.43	5,204.94	16,876.20	15,381.13	21,148.66
4	Expenses						
	a) Cost of materials consumed	2,625.43	2,731.62	2,535.84	8,336.35	6,871.55	10,491.63
	b) Purchase of Stock-in-trade	277.19	178.48	189.25	537.29	464.65	694.10
	c) Changes in inventories of finished goods, Stock-in-trade and work-in-progress	289.66	-45.09	-204.15	153.82	-87.62	-1,123.61
	d) Employees benefits expenses	1,282.50	1,256.52	1,097.08	3,684.27	3,265.04	4,462.91
	f) Finance costs	328.77	311.14	231.69	905.69	659.18	924.32
	g) Depreciation and amortization expense	116.60	115.16	156.86	374.86	476.54	672.80
	h) Other expenses	732.98	1,177.43	980.37	2,611.04	3,155.30	4,181.04
	Total Expense - (IV)	5,653.12	5,725.26	4,986.94	16,603.32	14,804.64	20,303.19
5	Profit before Exceptional item and Tax (III-IV)	31.51	116.17	218.00	272.88	576.49	845.46
6	Exceptional	-	-	-	0	-	0
7	Profit/ (Loss) before Tax (V-VI)	31.51	116.17	218.00	272.88	576.49	845.46
8	Tax Expense	13.58	69.94	44.26	-24.79	129.76	251.63
9	Net Profit for the period	17.93	46.23	173.74	297.68	446.73	593.83
10	Other Comprehensive Income, net of Income Tax						
	- Items that may be reclassified to Profit or loss	-	-	-	-	-	-
	- Items that may not be reclassified to Profit or loss	-	-	-12.88	-	-38.64	-29.09
	Total Other Comprehensive income, net of Income Tax	-	-	-12.88	-	-38.64	-29.09
11	Total Comprehensive income (9+10)	17.93	46.23	160.86	297.68	408.09	564.74
12	Paid up Equity Share Capital (Face value ₹ 10 per share)	1,417.24	1,417.24	1,417.24	1,417.24	1,417.24	1,417.24
13	Reserves	-	-	-	-	-	-
14	Earnings per share (Face value of ₹ 10 each)						
	Basic - in ₹	0.13	0.33	1.23	2.10	3.15	3.98
	Diluted - in ₹	0.13	0.33	1.23	2.10	3.15	3.98




Notes:

1. The unaudited financial statements has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13th February, 2019. The results have been reviewed by the Statutory Auditor of the Company.
2. The standalone financial results has been prepared in accordance with the Companies(Indian Accounting Standards) Rules, 2015(IND AS), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies to the extent applicable.
- 3 The format for unaudited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated 30 November 2015 has been modified to comply with the requirements of SEBI's circular dated 5 July 2016, IND AS and Schedule III(Division II) to the Companies Act, 2013, which are applicable to Companies that are required to comply with Ind AS.
4. The other income includes the interest component of the advances given by the Company to its subsidiaries.
5. As the Company deals with single product i.e., pharmaceuticals, segment wise figures are not furnished.
6. The effect on OCI has not been provided for quarter and nine months ended 31st December, 2018 though the impact on total comprehensive income is immaterial.

By the order of Board of Directors
For Bal Pharma Limited


Shailesh D Siroya
Managing Director



Place: Bengaluru
Date: 13.02.2019



Independent Auditor's Limited Review Report

To the Board of Directors of Bal Pharma Limited

We have reviewed the accompanying statement of unaudited standalone financial results of BAL PHARMA LIMITED ("the Company") for the quarter and the year to date results for the period from 1st April, 2018 to 31 December, 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015, as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July 2016 and Circular No. CIR/IMD/DF1/69/2016 dated 10th August, 2016.

The statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.


We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information performed by the Independent auditor of the Entity* issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A Review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that caused us to believe that the accompanying Statement of unaudited standalone financial statements, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013, read with



relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and disclosure Requirements) Regulations 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NSVM & Associates
Chartered Accountants
FRN:010072S



G C S Mani
Partner
MM No: 036508

Place : Bengaluru

Date : 13th February, 2019